Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 15 pages · English
Earlier from Tetratherix
- Executed Henry Schein Agreement
- TetraDerm Cohort 2
- Q1FY26 Quarterly Activities Report/Appendix 4C
- 2025 Financial Results Investor Presentation
- 2025 Financial Results Announcement
Later from Tetratherix
- TetraDerm Cohort 1 Results
- Half Yearly Report and Accounts
- Tutelix Update
- Precision medicine franchise launch and new revenue
- Successful Completion $15M Placement
Follow Tetratherix into a list and get an email when it puts out news.
Follow Tetratherix